Johnson & Johnson seeks FDA approval for SPRAVATO in treatment-resistant depression

By on    Pharma Industry News  

Johnson & Johnson seeks FDA approval for SPRAVATO in treatment-resistant depression

Johnson & Johnson (NYSE: JNJ) is seeking U.S. Food and Drug Administration (FDA) approval for SPRAVATO (esketamine) as a standalone treatment for adults with treatment-resistant depression (TRD). This application marks a significant milestone in the treatment of major depressive disorder (MDD). The American pharma major has submitted a supplemental New Drug Application (sNDA) to the […]

Esketamine nasal spray misses key trial expectations, but Janssen remains optimistic

By on    Pharma Industry News  

Esketamine nasal spray misses key trial expectations, but Janssen remains optimistic

Janssen Pharmaceutical Companies of Johnson & Johnson encountered a significant setback with their esketamine nasal spray in a phase 3 trial aimed at treating patients with treatment-resistant depression. The trial’s results revealed that esketamine did not meet its primary endpoint, sparking concern among industry experts and stakeholders. The late-stage study assessed the efficacy of two […]